Last reviewed · How we verify
Peginterferon alfa-2a, Ribavirin, epoetin-β
Peginterferon alfa-2a, Ribavirin, epoetin-β is a Antiviral combination therapy with hematopoietic agent Small molecule drug developed by Germans Trias i Pujol Hospital. It is currently FDA-approved for Chronic hepatitis C virus infection (genotype-dependent), Hepatitis C with compensated cirrhosis.
This combination therapy enhances immune response against hepatitis C virus while supporting red blood cell production to counteract treatment-induced anemia.
This combination therapy enhances immune response against hepatitis C virus while supporting red blood cell production to counteract treatment-induced anemia. Used for Chronic hepatitis C virus infection (genotype-dependent), Hepatitis C with compensated cirrhosis.
At a glance
| Generic name | Peginterferon alfa-2a, Ribavirin, epoetin-β |
|---|---|
| Sponsor | Germans Trias i Pujol Hospital |
| Drug class | Antiviral combination therapy with hematopoietic agent |
| Target | Interferon-α receptor; viral RNA polymerase; erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Peginterferon alfa-2a is an interferon that activates innate and adaptive immune responses to suppress viral replication. Ribavirin is a nucleoside analog that inhibits viral RNA synthesis. Epoetin-β (erythropoietin) stimulates red blood cell production to manage anemia caused by the antiviral agents.
Approved indications
- Chronic hepatitis C virus infection (genotype-dependent)
- Hepatitis C with compensated cirrhosis
Common side effects
- Anemia
- Flu-like symptoms (fever, fatigue, myalgia)
- Headache
- Nausea
- Neutropenia
- Thrombocytopenia
- Depression/mood changes
- Insomnia
Key clinical trials
- Peginterferon Alfa-2a, Ribavirin and Epoetin β in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens (PHASE4)
- Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV (PHASE4)
- High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (PHASE4)
- Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peginterferon alfa-2a, Ribavirin, epoetin-β CI brief — competitive landscape report
- Peginterferon alfa-2a, Ribavirin, epoetin-β updates RSS · CI watch RSS
- Germans Trias i Pujol Hospital portfolio CI
Frequently asked questions about Peginterferon alfa-2a, Ribavirin, epoetin-β
What is Peginterferon alfa-2a, Ribavirin, epoetin-β?
How does Peginterferon alfa-2a, Ribavirin, epoetin-β work?
What is Peginterferon alfa-2a, Ribavirin, epoetin-β used for?
Who makes Peginterferon alfa-2a, Ribavirin, epoetin-β?
What drug class is Peginterferon alfa-2a, Ribavirin, epoetin-β in?
What development phase is Peginterferon alfa-2a, Ribavirin, epoetin-β in?
What are the side effects of Peginterferon alfa-2a, Ribavirin, epoetin-β?
What does Peginterferon alfa-2a, Ribavirin, epoetin-β target?
Related
- Drug class: All Antiviral combination therapy with hematopoietic agent drugs
- Target: All drugs targeting Interferon-α receptor; viral RNA polymerase; erythropoietin receptor
- Manufacturer: Germans Trias i Pujol Hospital — full pipeline
- Therapeutic area: All drugs in Virology/Hepatology
- Indication: Drugs for Chronic hepatitis C virus infection (genotype-dependent)
- Indication: Drugs for Hepatitis C with compensated cirrhosis
- Compare: Peginterferon alfa-2a, Ribavirin, epoetin-β vs similar drugs
- Pricing: Peginterferon alfa-2a, Ribavirin, epoetin-β cost, discount & access